Posted by Michael Wonder on 29 Jun 2021
Roche’s Enspryng approved by European Commission as first and only at home subcutaneous treatment for neuromyelitis optica spectrum disorder
28 June 2021 - In Phase 3 trials, ENSPRYNG significantly reduced the number and severity of relapses in people with AQP4-IgG seropositive NMOSD.
Roche announced today that the European Commission has approved Enspryng (satralizumab) for the treatment of adults and adolescents from 12 years of age living with anti-aquaporin-4 antibody seropositive neuromyelitis optica spectrum disorder (NMOSD), as a monotherapy or in combination with immunosuppressive therapy.
Enspryng is the first and only NMOSD treatment that is administered subcutaneously every four weeks, allowing home-dosing after appropriate training.
